XML 41 R33.htm IDEA: XBRL DOCUMENT
v3.19.2

Product Sales Analysis - Q2 2019 (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2018 | Sep. 30, 2018 | Jun. 30, 2018 | Mar. 31, 2018 | Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Jun. 30, 2019
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 5,718 | $ 5,465 | $ 5,768 | $ 5,266 | $ 5,030 | $ 4,985 | $ 5,487 | $ 4,882 | $ 4,940 | $ 4,843 | $ 1,540
Actual %, year-on-year | 14.00% |  |  |  |  |  |  |  |  |  | 16.00%
CER %, year-on-year | 19.00% |  |  |  |  |  |  |  |  |  | 19.00%
Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 1,947 |  |  |  |  |  |  |  |  |  | $ 3,951
Actual %, year-on-year | 17.00% |  |  |  |  |  |  |  |  |  | 15.00%
CER %, year-on-year | 27.00% |  |  |  |  |  |  |  |  |  | 24.00%
US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 1,877 |  |  |  |  |  |  |  |  |  | $ 3,663
Actual %, year-on-year | 16.00% |  |  |  |  |  |  |  |  |  | 18.00%
Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 1,047 |  |  |  |  |  |  |  |  |  | $ 2,029
Actual %, year-on-year | 1.00% |  |  |  |  |  |  |  |  |  | (6.00%)
CER %, year-on-year | 8.00% |  |  |  |  |  |  |  |  |  | (1.00%)
World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 847 |  |  |  |  |  |  |  |  |  | $ 11,183
Actual %, year-on-year | 17.00% |  |  |  |  |  |  |  |  |  | 12.00%
CER %, year-on-year | 21.00% |  |  |  |  |  |  |  |  |  | 17.00%
Oncology |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 2,167 | 1,892 | 1,767 | 1,597 | 1,434 | 1,230 | 1,120 | 1,026 | 993 | 885 | $ 740
Actual %, year-on-year | 51.00% |  |  |  |  |  |  |  |  |  | 65.00%
CER %, year-on-year | 57.00% |  |  |  |  |  |  |  |  |  | 69.00%
Oncology | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 558 |  |  |  |  |  |  |  |  |  | $ 1,048
Actual %, year-on-year | 45.00% |  |  |  |  |  |  |  |  |  | 40.00%
CER %, year-on-year | 57.00% |  |  |  |  |  |  |  |  |  | 52.00%
Oncology | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 851 |  |  |  |  |  |  |  |  |  | $ 1,621
Actual %, year-on-year | 58.00% |  |  |  |  |  |  |  |  |  | 68.00%
Oncology | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 336 |  |  |  |  |  |  |  |  |  | $ 650
Actual %, year-on-year | 31.00% |  |  |  |  |  |  |  |  |  | 29.00%
CER %, year-on-year | 41.00% |  |  |  |  |  |  |  |  |  | 37.00%
Oncology | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 422 |  |  |  |  |  |  |  |  |  | $ 4,059
Actual %, year-on-year | 65.00% |  |  |  |  |  |  |  |  |  | 52.00%
CER %, year-on-year | 70.00% |  |  |  |  |  |  |  |  |  | 58.00%
Tagrisso |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 784 | 630 | 594 | 506 | 422 | 338 | 304 | 248 | 232 | 171 | $ 314
Actual %, year-on-year | 86.00% |  |  |  |  |  |  |  |  |  |
CER %, year-on-year | 92.00% |  |  |  |  |  |  |  |  |  |
Tagrisso | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 191 |  |  |  |  |  |  |  |  |  | 329
Tagrisso | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 300 |  |  |  |  |  |  |  |  |  | $ 559
Actual %, year-on-year | 55.00% |  |  |  |  |  |  |  |  |  | 64.00%
Tagrisso | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 112 |  |  |  |  |  |  |  |  |  | $ 212
Actual %, year-on-year | 60.00% |  |  |  |  |  |  |  |  |  | 53.00%
CER %, year-on-year | 73.00% |  |  |  |  |  |  |  |  |  | 64.00%
Tagrisso | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 181 |  |  |  |  |  |  |  |  |  | $ 1,414
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | 86.00%
CER %, year-on-year |  |  |  |  |  |  |  |  |  |  | 92.00%
Imfinzi |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 338 | 295 | 262 | 187 | 122 | 62 | 18 |  | 1 |  | $ 88
Imfinzi | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 6 |  |  |  |  |  |  |  |  |  | 12
Imfinzi | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 242 |  |  |  |  |  |  |  |  |  | 473
Imfinzi | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 37 |  |  |  |  |  |  |  |  |  | 60
Imfinzi | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 53 |  |  |  |  |  |  |  |  |  | 633
Lynparza |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 283 | 237 | 209 | 169 | 150 | 119 | 100 | 81 | 59 | 57 | 68
Actual %, year-on-year | 89.00% |  |  |  |  |  |  |  |  |  |
CER %, year-on-year | 95.00% |  |  |  |  |  |  |  |  |  |
Lynparza | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 33 |  |  |  |  |  |  |  |  |  | 59
Lynparza | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 143 |  |  |  |  |  |  |  |  |  | $ 262
Actual %, year-on-year | 72.00% |  |  |  |  |  |  |  |  |  | 76.00%
Lynparza | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 66 |  |  |  |  |  |  |  |  |  | $ 131
Actual %, year-on-year | 47.00% |  |  |  |  |  |  |  |  |  | 51.00%
CER %, year-on-year | 60.00% |  |  |  |  |  |  |  |  |  | 61.00%
Lynparza | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 41 |  |  |  |  |  |  |  |  |  | $ 520
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | 93.00%
Iressa |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 118 | 134 | 112 | 131 | 143 | 132 | 130 | 137 | 137 | 124 | $ 34
Actual %, year-on-year | (17.00%) |  |  |  |  |  |  |  |  |  | (35.00%)
CER %, year-on-year | (13.00%) |  |  |  |  |  |  |  |  |  | (33.00%)
Iressa | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 78 |  |  |  |  |  |  |  |  |  | $ 164
Actual %, year-on-year | 1.00% |  |  |  |  |  |  |  |  |  | 11.00%
CER %, year-on-year | 8.00% |  |  |  |  |  |  |  |  |  | 18.00%
Iressa | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 4 |  |  |  |  |  |  |  |  |  | $ 8
Actual %, year-on-year | (33.00%) |  |  |  |  |  |  |  |  |  | (43.00%)
Iressa | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 20 |  |  |  |  |  |  |  |  |  | $ 46
Actual %, year-on-year | (35.00%) |  |  |  |  |  |  |  |  |  | (25.00%)
CER %, year-on-year | (32.00%) |  |  |  |  |  |  |  |  |  | (20.00%)
Iressa | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 16 |  |  |  |  |  |  |  |  |  | $ 252
Actual %, year-on-year | (45.00%) |  |  |  |  |  |  |  |  |  | (8.00%)
CER %, year-on-year | (41.00%) |  |  |  |  |  |  |  |  |  | (3.00%)
Calquence |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 35 | 29 | 24 | 18 | 12 | 8 | 3 |  |  |  |
Calquence | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 35 |  |  |  |  |  |  |  |  |  | $ 64
Calquence | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales |  |  |  |  |  |  |  |  |  |  | 64
Faslodex |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 267 | 254 | 269 | 258 | 247 | 254 | 238 | 241 | 248 | 214 | $ 64
Actual %, year-on-year | 8.00% |  |  |  |  |  |  |  |  |  | 21.00%
CER %, year-on-year | 12.00% |  |  |  |  |  |  |  |  |  | 23.00%
Faslodex | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 51 |  |  |  |  |  |  |  |  |  | $ 96
Actual %, year-on-year | 59.00% |  |  |  |  |  |  |  |  |  | 35.00%
CER %, year-on-year | 75.00% |  |  |  |  |  |  |  |  |  | 49.00%
Faslodex | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 125 |  |  |  |  |  |  |  |  |  | $ 251
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | (3.00%)
Faslodex | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 56 |  |  |  |  |  |  |  |  |  | $ 110
Actual %, year-on-year | (5.00%) |  |  |  |  |  |  |  |  |  | (7.00%)
CER %, year-on-year | 2.00% |  |  |  |  |  |  |  |  |  |
Faslodex | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 35 |  |  |  |  |  |  |  |  |  | $ 521
Actual %, year-on-year | 13.00% |  |  |  |  |  |  |  |  |  | 4.00%
CER %, year-on-year | 16.00% |  |  |  |  |  |  |  |  |  | 8.00%
Zoladex |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 197 | 194 | 182 | 194 | 192 | 184 | 187 | 185 | 178 | 185 | $ 87
Actual %, year-on-year | 3.00% |  |  |  |  |  |  |  |  |  | (16.00%)
CER %, year-on-year | 10.00% |  |  |  |  |  |  |  |  |  | (13.00%)
Zoladex | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 121 |  |  |  |  |  |  |  |  |  | $ 235
Actual %, year-on-year | 20.00% |  |  |  |  |  |  |  |  |  | 16.00%
CER %, year-on-year | 31.00% |  |  |  |  |  |  |  |  |  | 27.00%
Zoladex | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 2 |  |  |  |  |  |  |  |  |  | $ 4
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | 33.00%
Zoladex | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 30 |  |  |  |  |  |  |  |  |  | $ 65
Actual %, year-on-year | (12.00%) |  |  |  |  |  |  |  |  |  | (4.00%)
CER %, year-on-year | (6.00%) |  |  |  |  |  |  |  |  |  | 1.00%
Zoladex | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 44 |  |  |  |  |  |  |  |  |  | $ 391
Actual %, year-on-year | (20.00%) |  |  |  |  |  |  |  |  |  | 4.00%
CER %, year-on-year | (16.00%) |  |  |  |  |  |  |  |  |  | 11.00%
Arimidex |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 60 | 51 | 46 | 55 | 57 | 54 | 57 | 54 | 54 | 52 | $ 24
Actual %, year-on-year | 5.00% |  |  |  |  |  |  |  |  |  | (4.00%)
CER %, year-on-year | 14.00% |  |  |  |  |  |  |  |  |  | (4.00%)
Arimidex | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 36 |  |  |  |  |  |  |  |  |  | $ 72
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | 1.00%
CER %, year-on-year | 14.00% |  |  |  |  |  |  |  |  |  | 13.00%
Arimidex | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 9 |  |  |  |  |  |  |  |  |  | $ 15
Actual %, year-on-year | 29.00% |  |  |  |  |  |  |  |  |  |
CER %, year-on-year | 29.00% |  |  |  |  |  |  |  |  |  |
Arimidex | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 15 |  |  |  |  |  |  |  |  |  | $ 111
Actual %, year-on-year | 7.00% |  |  |  |  |  |  |  |  |  |
CER %, year-on-year | 7.00% |  |  |  |  |  |  |  |  |  | 7.00%
Casodex |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 57 | 48 | 46 | 51 | 52 | 52 | 54 | 51 | 54 | 56 | $ 32
Actual %, year-on-year | 10.00% |  |  |  |  |  |  |  |  |  | (6.00%)
CER %, year-on-year | 17.00% |  |  |  |  |  |  |  |  |  | (3.00%)
Casodex | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 34 |  |  |  |  |  |  |  |  |  | $ 65
Actual %, year-on-year | 21.00% |  |  |  |  |  |  |  |  |  | 10.00%
CER %, year-on-year | 32.00% |  |  |  |  |  |  |  |  |  | 19.00%
Casodex | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 4 |  |  |  |  |  |  |  |  |  | $ 8
Actual %, year-on-year | (20.00%) |  |  |  |  |  |  |  |  |  | (27.00%)
CER %, year-on-year | (20.00%) |  |  |  |  |  |  |  |  |  | (27.00%)
Casodex | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 19 |  |  |  |  |  |  |  |  |  | $ 105
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | 1.00%
CER %, year-on-year | 5.00% |  |  |  |  |  |  |  |  |  | 7.00%
Oncology, Others |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 28 | 20 | 23 | 28 | 37 | 27 | 29 | 29 | 30 | 26 | $ 29
Actual %, year-on-year | (24.00%) |  |  |  |  |  |  |  |  |  | (36.00%)
CER %, year-on-year | (24.00%) |  |  |  |  |  |  |  |  |  | (36.00%)
Oncology, Others | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 8 |  |  |  |  |  |  |  |  |  | $ 16
Actual %, year-on-year | (11.00%) |  |  |  |  |  |  |  |  |  |
CER %, year-on-year | (11.00%) |  |  |  |  |  |  |  |  |  | 6.00%
Oncology, Others | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 2 |  |  |  |  |  |  |  |  |  | $ 3
Oncology, Others | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 18 |  |  |  |  |  |  |  |  |  | $ 48
Actual %, year-on-year | (31.00%) |  |  |  |  |  |  |  |  |  | (25.00%)
CER %, year-on-year | (31.00%) |  |  |  |  |  |  |  |  |  | (23.00%)
BioPharmaceuticals, CVRM |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 1,658 | 1,714 | 1,747 | 1,695 | 1,623 | 1,645 | 1,939 | 1,773 | 1,775 | 1,779 | $ 273
Actual %, year-on-year | 2.00% |  |  |  |  |  |  |  |  |  |
CER %, year-on-year | 7.00% |  |  |  |  |  |  |  |  |  | 3.00%
BioPharmaceuticals, CVRM | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 701 |  |  |  |  |  |  |  |  |  | $ 1,448
Actual %, year-on-year | 10.00% |  |  |  |  |  |  |  |  |  | 9.00%
CER %, year-on-year | 19.00% |  |  |  |  |  |  |  |  |  | 18.00%
BioPharmaceuticals, CVRM | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 527 |  |  |  |  |  |  |  |  |  | $ 1,085
Actual %, year-on-year | (1.00%) |  |  |  |  |  |  |  |  |  | 5.00%
BioPharmaceuticals, CVRM | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 283 |  |  |  |  |  |  |  |  |  | $ 566
Actual %, year-on-year | (8.00%) |  |  |  |  |  |  |  |  |  | (10.00%)
CER %, year-on-year | (1.00%) |  |  |  |  |  |  |  |  |  | (5.00%)
BioPharmaceuticals, CVRM | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 147 |  |  |  |  |  |  |  |  |  | $ 3,372
Actual %, year-on-year | (1.00%) |  |  |  |  |  |  |  |  |  | 3.00%
CER %, year-on-year | 2.00% |  |  |  |  |  |  |  |  |  | 8.00%
Farxiga |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 377 | 349 | 397 | 355 | 340 | 299 | 332 | 285 | 250 | 207 | $ 72
Actual %, year-on-year | 11.00% |  |  |  |  |  |  |  |  |  | 13.00%
CER %, year-on-year | 16.00% |  |  |  |  |  |  |  |  |  | 16.00%
Farxiga | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 111 |  |  |  |  |  |  |  |  |  | $ 206
Actual %, year-on-year | 26.00% |  |  |  |  |  |  |  |  |  | 31.00%
CER %, year-on-year | 40.00% |  |  |  |  |  |  |  |  |  | 45.00%
Farxiga | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 139 |  |  |  |  |  |  |  |  |  | $ 270
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | 2.00%
Farxiga | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 89 |  |  |  |  |  |  |  |  |  | $ 178
Actual %, year-on-year | 14.00% |  |  |  |  |  |  |  |  |  | 17.00%
CER %, year-on-year | 22.00% |  |  |  |  |  |  |  |  |  | 26.00%
Farxiga | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 38 |  |  |  |  |  |  |  |  |  | $ 726
Actual %, year-on-year | 9.00% |  |  |  |  |  |  |  |  |  | 14.00%
CER %, year-on-year | 9.00% |  |  |  |  |  |  |  |  |  | 19.00%
Brilinta |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 389 | 348 | 376 | 336 | 316 | 293 | 299 | 284 | 272 | 224 | $ 28
Actual %, year-on-year | 23.00% |  |  |  |  |  |  |  |  |  | (7.00%)
CER %, year-on-year | 28.00% |  |  |  |  |  |  |  |  |  |
Brilinta | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 120 |  |  |  |  |  |  |  |  |  | $ 217
Actual %, year-on-year | 67.00% |  |  |  |  |  |  |  |  |  | 47.00%
CER %, year-on-year | 79.00% |  |  |  |  |  |  |  |  |  | 58.00%
Brilinta | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 168 |  |  |  |  |  |  |  |  |  | $ 321
Actual %, year-on-year | 17.00% |  |  |  |  |  |  |  |  |  | 24.00%
Brilinta | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 88 |  |  |  |  |  |  |  |  |  | $ 171
Actual %, year-on-year | 2.00% |  |  |  |  |  |  |  |  |  | (1.00%)
CER %, year-on-year | 10.00% |  |  |  |  |  |  |  |  |  | 7.00%
Brilinta | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 13 |  |  |  |  |  |  |  |  |  | $ 737
Actual %, year-on-year | (7.00%) |  |  |  |  |  |  |  |  |  | 21.00%
CER %, year-on-year |  |  |  |  |  |  |  |  |  |  | 26.00%
Onglyza |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 116 | 153 | 148 | 140 | 126 | 129 | 180 | 127 | 150 | 154 | $ 26
Actual %, year-on-year | (8.00%) |  |  |  |  |  |  |  |  |  | (10.00%)
CER %, year-on-year | (4.00%) |  |  |  |  |  |  |  |  |  | (7.00%)
Onglyza | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 44 |  |  |  |  |  |  |  |  |  | $ 87
Actual %, year-on-year | 7.00% |  |  |  |  |  |  |  |  |  | 7.00%
CER %, year-on-year | 10.00% |  |  |  |  |  |  |  |  |  | 16.00%
Onglyza | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 42 |  |  |  |  |  |  |  |  |  | $ 120
Actual %, year-on-year | (14.00%) |  |  |  |  |  |  |  |  |  | 22.00%
Onglyza | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 17 |  |  |  |  |  |  |  |  |  | $ 36
Actual %, year-on-year | (29.00%) |  |  |  |  |  |  |  |  |  | (23.00%)
CER %, year-on-year | (17.00%) |  |  |  |  |  |  |  |  |  | (17.00%)
Onglyza | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 13 |  |  |  |  |  |  |  |  |  | $ 269
Actual %, year-on-year | 8.00% |  |  |  |  |  |  |  |  |  | 5.00%
CER %, year-on-year | 17.00% |  |  |  |  |  |  |  |  |  | 10.00%
Bydureon |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 141 | 142 | 138 | 152 | 155 | 139 | 147 | 128 | 146 | 153 | $ 8
Actual %, year-on-year | (9.00%) |  |  |  |  |  |  |  |  |  | (20.00%)
CER %, year-on-year | (8.00%) |  |  |  |  |  |  |  |  |  | (20.00%)
Bydureon | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 5 |  |  |  |  |  |  |  |  |  | $ 7
Actual %, year-on-year | (29.00%) |  |  |  |  |  |  |  |  |  |
CER %, year-on-year | (14.00%) |  |  |  |  |  |  |  |  |  | 29.00%
Bydureon | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 117 |  |  |  |  |  |  |  |  |  | $ 234
Actual %, year-on-year | (5.00%) |  |  |  |  |  |  |  |  |  |
Bydureon | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 16 |  |  |  |  |  |  |  |  |  | $ 34
Actual %, year-on-year | (20.00%) |  |  |  |  |  |  |  |  |  | (21.00%)
CER %, year-on-year | (20.00%) |  |  |  |  |  |  |  |  |  | (19.00%)
Bydureon | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 3 |  |  |  |  |  |  |  |  |  | $ 283
Actual %, year-on-year | (40.00%) |  |  |  |  |  |  |  |  |  | (4.00%)
CER %, year-on-year | (40.00%) |  |  |  |  |  |  |  |  |  | (3.00%)
Byetta |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 25 | 30 | 32 | 34 | 29 | 31 | 48 | 39 | 43 | 46 | $ 6
Actual %, year-on-year | (14.00%) |  |  |  |  |  |  |  |  |  | (25.00%)
CER %, year-on-year | (10.00%) |  |  |  |  |  |  |  |  |  | (25.00%)
Byetta | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 3 |  |  |  |  |  |  |  |  |  | $ 4
CER %, year-on-year |  |  |  |  |  |  |  |  |  |  | 50.00%
Byetta | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 15 |  |  |  |  |  |  |  |  |  | $ 35
Actual %, year-on-year | (12.00%) |  |  |  |  |  |  |  |  |  | 9.00%
Byetta | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 4 |  |  |  |  |  |  |  |  |  | $ 10
Actual %, year-on-year | (56.00%) |  |  |  |  |  |  |  |  |  | (38.00%)
CER %, year-on-year | (56.00%) |  |  |  |  |  |  |  |  |  | (38.00%)
Byetta | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 3 |  |  |  |  |  |  |  |  |  | $ 55
Actual %, year-on-year | (25.00%) |  |  |  |  |  |  |  |  |  | (8.00%)
CER %, year-on-year | (25.00%) |  |  |  |  |  |  |  |  |  | (5.00%)
Symlin |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 8 | 7 | 10 | 8 | 7 | 9 | 13 | 10 | 11 | 14 |
Actual %, year-on-year | 14.00% |  |  |  |  |  |  |  |  |  |
CER %, year-on-year | 14.00% |  |  |  |  |  |  |  |  |  |
Symlin | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 8 |  |  |  |  |  |  |  |  |  | $ 15
Actual %, year-on-year | 14.00% |  |  |  |  |  |  |  |  |  | (6.00%)
Symlin | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales |  |  |  |  |  |  |  |  |  |  | $ 15
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | (6.00%)
CER %, year-on-year |  |  |  |  |  |  |  |  |  |  | (6.00%)
Crestor |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 310 | 335 | 353 | 353 | 338 | 389 | 594 | 580 | 560 | 631 | $ 109
Actual %, year-on-year | (8.00%) |  |  |  |  |  |  |  |  |  | 7.00%
CER %, year-on-year | (3.00%) |  |  |  |  |  |  |  |  |  | 11.00%
Crestor | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 182 |  |  |  |  |  |  |  |  |  | $ 407
Actual %, year-on-year | (2.00%) |  |  |  |  |  |  |  |  |  | (4.00%)
CER %, year-on-year | 4.00% |  |  |  |  |  |  |  |  |  | 2.00%
Crestor | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 28 |  |  |  |  |  |  |  |  |  | $ 54
Actual %, year-on-year | (36.00%) |  |  |  |  |  |  |  |  |  | (40.00%)
Crestor | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 36 |  |  |  |  |  |  |  |  |  | $ 75
Actual %, year-on-year | (22.00%) |  |  |  |  |  |  |  |  |  | (32.00%)
CER %, year-on-year | (13.00%) |  |  |  |  |  |  |  |  |  | (27.00%)
Crestor | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 64 |  |  |  |  |  |  |  |  |  | $ 645
Actual %, year-on-year | 3.00% |  |  |  |  |  |  |  |  |  | (11.00%)
CER %, year-on-year | 8.00% |  |  |  |  |  |  |  |  |  | (6.00%)
Seloken/Toprol-XL |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 168 | 225 | 160 | 179 | 173 | 200 | 168 | 160 | 181 | 186 | $ 5
Actual %, year-on-year | (3.00%) |  |  |  |  |  |  |  |  |  | (29.00%)
CER %, year-on-year | 5.00% |  |  |  |  |  |  |  |  |  | (29.00%)
Seloken/Toprol-XL | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 156 |  |  |  |  |  |  |  |  |  | $ 349
Actual %, year-on-year | 1.00% |  |  |  |  |  |  |  |  |  | 6.00%
CER %, year-on-year | 10.00% |  |  |  |  |  |  |  |  |  | 16.00%
Seloken/Toprol-XL | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 3 |  |  |  |  |  |  |  |  |  | $ 26
Actual %, year-on-year | (63.00%) |  |  |  |  |  |  |  |  |  |
Seloken/Toprol-XL | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 7 |  |  |  |  |  |  |  |  |  | $ 13
Actual %, year-on-year | 17.00% |  |  |  |  |  |  |  |  |  | 8.00%
CER %, year-on-year | 17.00% |  |  |  |  |  |  |  |  |  | 8.00%
Seloken/Toprol-XL | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 2 |  |  |  |  |  |  |  |  |  | $ 393
Actual %, year-on-year | (50.00%) |  |  |  |  |  |  |  |  |  | 5.00%
CER %, year-on-year | (50.00%) |  |  |  |  |  |  |  |  |  | 14.00%
Atacand |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 56 | 50 | 58 | 65 | 66 | 71 | 73 | 80 | 72 | 75 | $ 9
Actual %, year-on-year | (14.00%) |  |  |  |  |  |  |  |  |  | (10.00%)
CER %, year-on-year | (9.00%) |  |  |  |  |  |  |  |  |  | (10.00%)
Atacand | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 37 |  |  |  |  |  |  |  |  |  | $ 76
Actual %, year-on-year | (3.00%) |  |  |  |  |  |  |  |  |  | 1.00%
CER %, year-on-year | 5.00% |  |  |  |  |  |  |  |  |  | 11.00%
Atacand | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 4 |  |  |  |  |  |  |  |  |  | $ 6
Actual %, year-on-year | 33.00% |  |  |  |  |  |  |  |  |  | (40.00%)
Atacand | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 11 |  |  |  |  |  |  |  |  |  | $ 15
Actual %, year-on-year | (42.00%) |  |  |  |  |  |  |  |  |  | (63.00%)
CER %, year-on-year | (42.00%) |  |  |  |  |  |  |  |  |  | (63.00%)
Atacand | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 4 |  |  |  |  |  |  |  |  |  | $ 106
Actual %, year-on-year | (20.00%) |  |  |  |  |  |  |  |  |  | (21.00%)
CER %, year-on-year | (20.00%) |  |  |  |  |  |  |  |  |  | (16.00%)
CVRM, Others |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 68 | 75 | 75 | 73 | 73 | 85 | 80 | 80 | 90 | 89 | $ 10
Actual %, year-on-year | (7.00%) |  |  |  |  |  |  |  |  |  | (23.00%)
CER %, year-on-year | (4.00%) |  |  |  |  |  |  |  |  |  | (23.00%)
CVRM, Others | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 43 |  |  |  |  |  |  |  |  |  | $ 95
Actual %, year-on-year | (12.00%) |  |  |  |  |  |  |  |  |  | (13.00%)
CER %, year-on-year | (8.00%) |  |  |  |  |  |  |  |  |  | (6.00%)
CVRM, Others | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 3 |  |  |  |  |  |  |  |  |  | $ 4
CVRM, Others | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 15 |  |  |  |  |  |  |  |  |  | $ 34
Actual %, year-on-year | (17.00%) |  |  |  |  |  |  |  |  |  | (13.00%)
CER %, year-on-year | (17.00%) |  |  |  |  |  |  |  |  |  | (13.00%)
CVRM, Others | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 7 |  |  |  |  |  |  |  |  |  | $ 143
Actual %, year-on-year | (13.00%) |  |  |  |  |  |  |  |  |  | (10.00%)
CER %, year-on-year | (13.00%) |  |  |  |  |  |  |  |  |  | (6.00%)
BioPharmaceuticals, Respiratory |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 1,252 | 1,283 | 1,362 | 1,142 | 1,226 | 1,181 | 1,334 | 1,092 | 1,099 | 1,181 | $ 262
Actual %, year-on-year | 2.00% |  |  |  |  |  |  |  |  |  | (14.00%)
CER %, year-on-year | 7.00% |  |  |  |  |  |  |  |  |  | (11.00%)
BioPharmaceuticals, Respiratory | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 438 |  |  |  |  |  |  |  |  |  | $ 956
Actual %, year-on-year | 26.00% |  |  |  |  |  |  |  |  |  | 22.00%
CER %, year-on-year | 36.00% |  |  |  |  |  |  |  |  |  | 30.00%
BioPharmaceuticals, Respiratory | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 410 |  |  |  |  |  |  |  |  |  | $ 756
Actual %, year-on-year | 1.00% |  |  |  |  |  |  |  |  |  | 12.00%
BioPharmaceuticals, Respiratory | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 276 |  |  |  |  |  |  |  |  |  | $ 561
Actual %, year-on-year | (13.00%) |  |  |  |  |  |  |  |  |  | (13.00%)
CER %, year-on-year | (7.00%) |  |  |  |  |  |  |  |  |  | (7.00%)
BioPharmaceuticals, Respiratory | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 128 |  |  |  |  |  |  |  |  |  | $ 2,535
Actual %, year-on-year | (18.00%) |  |  |  |  |  |  |  |  |  | 5.00%
CER %, year-on-year | (15.00%) |  |  |  |  |  |  |  |  |  | 10.00%
Symbicort |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 585 | 585 | 636 | 619 | 672 | 634 | 752 | 668 | 706 | 677 | $ 171
Actual %, year-on-year | (13.00%) |  |  |  |  |  |  |  |  |  | (20.00%)
CER %, year-on-year | (9.00%) |  |  |  |  |  |  |  |  |  | (17.00%)
Symbicort | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 130 |  |  |  |  |  |  |  |  |  | $ 263
Actual %, year-on-year | 15.00% |  |  |  |  |  |  |  |  |  | 9.00%
CER %, year-on-year | 25.00% |  |  |  |  |  |  |  |  |  | 18.00%
Symbicort | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 206 |  |  |  |  |  |  |  |  |  | $ 382
Actual %, year-on-year | (20.00%) |  |  |  |  |  |  |  |  |  | (13.00%)
Symbicort | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 172 |  |  |  |  |  |  |  |  |  | $ 354
Actual %, year-on-year | (14.00%) |  |  |  |  |  |  |  |  |  | (14.00%)
CER %, year-on-year | (7.00%) |  |  |  |  |  |  |  |  |  | (7.00%)
Symbicort | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 77 |  |  |  |  |  |  |  |  |  | $ 1,170
Actual %, year-on-year | (26.00%) |  |  |  |  |  |  |  |  |  | (10.00%)
CER %, year-on-year | (23.00%) |  |  |  |  |  |  |  |  |  | (6.00%)
Pulmicort |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 333 | 383 | 389 | 264 | 287 | 346 | 371 | 242 | 226 | 337 | $ 40
Actual %, year-on-year | 16.00% |  |  |  |  |  |  |  |  |  | (5.00%)
CER %, year-on-year | 23.00% |  |  |  |  |  |  |  |  |  | (2.00%)
Pulmicort | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 262 |  |  |  |  |  |  |  |  |  | $ 576
Actual %, year-on-year | 24.00% |  |  |  |  |  |  |  |  |  | 20.00%
CER %, year-on-year | 32.00% |  |  |  |  |  |  |  |  |  | 27.00%
Pulmicort | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 32 |  |  |  |  |  |  |  |  |  | $ 56
Actual %, year-on-year | 7.00% |  |  |  |  |  |  |  |  |  | (5.00%)
Pulmicort | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 19 |  |  |  |  |  |  |  |  |  | $ 44
Actual %, year-on-year | (17.00%) |  |  |  |  |  |  |  |  |  | (12.00%)
CER %, year-on-year | (9.00%) |  |  |  |  |  |  |  |  |  | (6.00%)
Pulmicort | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 20 |  |  |  |  |  |  |  |  |  | $ 716
Actual %, year-on-year | (9.00%) |  |  |  |  |  |  |  |  |  | 13.00%
CER %, year-on-year | (5.00%) |  |  |  |  |  |  |  |  |  | 19.00%
Fasenra |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 167 | 129 | 125 | 86 | 65 | 21 |  |  |  |  | $ 42
Fasenra | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 1 |  |  |  |  |  |  |  |  |  | 1
Fasenra | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 115 |  |  |  |  |  |  |  |  |  | 208
Fasenra | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 27 |  |  |  |  |  |  |  |  |  | 45
Fasenra | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 24 |  |  |  |  |  |  |  |  |  | 296
Daliresp/Daxas |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 56 | 48 | 54 | 52 | 45 | 38 | 53 | 53 | 48 | 44 | 1
Actual %, year-on-year | 24.00% |  |  |  |  |  |  |  |  |  |
CER %, year-on-year | 24.00% |  |  |  |  |  |  |  |  |  |
Daliresp/Daxas | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 1 |  |  |  |  |  |  |  |  |  | 2
Daliresp/Daxas | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 48 |  |  |  |  |  |  |  |  |  | $ 89
Actual %, year-on-year | 26.00% |  |  |  |  |  |  |  |  |  | 33.00%
Daliresp/Daxas | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 6 |  |  |  |  |  |  |  |  |  | $ 12
Actual %, year-on-year | (14.00%) |  |  |  |  |  |  |  |  |  | (14.00%)
CER %, year-on-year |  |  |  |  |  |  |  |  |  |  | (7.00%)
Daliresp/Daxas | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 1 |  |  |  |  |  |  |  |  |  | $ 104
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | 25.00%
CER %, year-on-year |  |  |  |  |  |  |  |  |  |  | 27.00%
Tudorza/Eklira |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 13 | 20 | 19 | 18 | 39 | 34 | 42 | 37 | 34 | 37 | $ 3
Actual %, year-on-year | (71.00%) |  |  |  |  |  |  |  |  |  | (50.00%)
CER %, year-on-year | (69.00%) |  |  |  |  |  |  |  |  |  | (50.00%)
Tudorza/Eklira | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ (2) |  |  |  |  |  |  |  |  |  | $ (1)
Tudorza/Eklira | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | (2) |  |  |  |  |  |  |  |  |  |
Tudorza/Eklira | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 15 |  |  |  |  |  |  |  |  |  | $ 31
Actual %, year-on-year | (17.00%) |  |  |  |  |  |  |  |  |  | (18.00%)
CER %, year-on-year | (11.00%) |  |  |  |  |  |  |  |  |  | (13.00%)
Tudorza/Eklira | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 2 |  |  |  |  |  |  |  |  |  | $ 33
Actual %, year-on-year | (50.00%) |  |  |  |  |  |  |  |  |  | (55.00%)
CER %, year-on-year | (50.00%) |  |  |  |  |  |  |  |  |  | (52.00%)
Duaklir |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 17 | 20 | 22 | 23 | 22 | 28 | 23 | 21 | 16 | 19 | $ 1
Actual %, year-on-year | (23.00%) |  |  |  |  |  |  |  |  |  | (50.00%)
CER %, year-on-year | (14.00%) |  |  |  |  |  |  |  |  |  | (50.00%)
Duaklir | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ (1) |  |  |  |  |  |  |  |  |  |
Duaklir | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 17 |  |  |  |  |  |  |  |  |  | $ 36
Actual %, year-on-year | (15.00%) |  |  |  |  |  |  |  |  |  | (23.00%)
CER %, year-on-year | (15.00%) |  |  |  |  |  |  |  |  |  | (19.00%)
Duaklir | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 1 |  |  |  |  |  |  |  |  |  | $ 37
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | (26.00%)
CER %, year-on-year |  |  |  |  |  |  |  |  |  |  | (20.00%)
Bevespi |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 10 | 10 | 10 | 10 | 8 | 5 | 8 | 4 | 3 | 1 |
Actual %, year-on-year | 25.00% |  |  |  |  |  |  |  |  |  |
CER %, year-on-year | 25.00% |  |  |  |  |  |  |  |  |  |
Bevespi | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 10 |  |  |  |  |  |  |  |  |  | $ 20
Actual %, year-on-year | 25.00% |  |  |  |  |  |  |  |  |  | 54.00%
Bevespi | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales |  |  |  |  |  |  |  |  |  |  | $ 20
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | 54.00%
CER %, year-on-year |  |  |  |  |  |  |  |  |  |  | 54.00%
Respiratory, Others |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 71 | 88 | 107 | 70 | 88 | 75 | 85 | 67 | 66 | 66 | $ 4
Actual %, year-on-year | (13.00%) |  |  |  |  |  |  |  |  |  | (85.00%)
CER %, year-on-year | (7.00%) |  |  |  |  |  |  |  |  |  | (85.00%)
Respiratory, Others | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 47 |  |  |  |  |  |  |  |  |  | $ 115
Actual %, year-on-year | 96.00% |  |  |  |  |  |  |  |  |  | 89.00%
Respiratory, Others | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 1 |  |  |  |  |  |  |  |  |  | $ 1
Respiratory, Others | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 20 |  |  |  |  |  |  |  |  |  | $ 39
Actual %, year-on-year | (55.00%) |  |  |  |  |  |  |  |  |  | (48.00%)
CER %, year-on-year | (55.00%) |  |  |  |  |  |  |  |  |  | (47.00%)
Respiratory, Others | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 3 |  |  |  |  |  |  |  |  |  | $ 159
Actual %, year-on-year | (79.00%) |  |  |  |  |  |  |  |  |  | (2.00%)
CER %, year-on-year | (79.00%) |  |  |  |  |  |  |  |  |  | 4.00%
Other medicines |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 641 | 576 | 892 | 832 | 747 | 929 | 1,094 | 991 | 1,073 | 998 | $ 265
Actual %, year-on-year | (14.00%) |  |  |  |  |  |  |  |  |  | (14.00%)
CER %, year-on-year | (10.00%) |  |  |  |  |  |  |  |  |  | (10.00%)
Other medicines | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 250 |  |  |  |  |  |  |  |  |  | $ 499
Actual %, year-on-year | (14.00%) |  |  |  |  |  |  |  |  |  | (11.00%)
CER %, year-on-year | (8.00%) |  |  |  |  |  |  |  |  |  | (7.00%)
Other medicines | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 89 |  |  |  |  |  |  |  |  |  | $ 201
Actual %, year-on-year | (37.00%) |  |  |  |  |  |  |  |  |  | (54.00%)
Other medicines | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 152 |  |  |  |  |  |  |  |  |  | $ 252
Actual %, year-on-year | (1.00%) |  |  |  |  |  |  |  |  |  | (33.00%)
CER %, year-on-year | 3.00% |  |  |  |  |  |  |  |  |  | (28.00%)
Other medicines | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 150 |  |  |  |  |  |  |  |  |  | $ 1,217
Actual %, year-on-year | (6.00%) |  |  |  |  |  |  |  |  |  | (27.00%)
CER %, year-on-year | (3.00%) |  |  |  |  |  |  |  |  |  | (24.00%)
Nexium |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 393 | 363 | 390 | 422 | 442 | 448 | 427 | 469 | 595 | 461 | $ 236
Actual %, year-on-year | (11.00%) |  |  |  |  |  |  |  |  |  | (1.00%)
CER %, year-on-year | (7.00%) |  |  |  |  |  |  |  |  |  | 2.00%
Nexium | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 179 |  |  |  |  |  |  |  |  |  | $ 369
Actual %, year-on-year | 11.00% |  |  |  |  |  |  |  |  |  | 8.00%
CER %, year-on-year | 19.00% |  |  |  |  |  |  |  |  |  | 15.00%
Nexium | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 53 |  |  |  |  |  |  |  |  |  | $ 119
Actual %, year-on-year | (39.00%) |  |  |  |  |  |  |  |  |  | (36.00%)
Nexium | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 16 |  |  |  |  |  |  |  |  |  | $ 32
Actual %, year-on-year | (74.00%) |  |  |  |  |  |  |  |  |  | (74.00%)
CER %, year-on-year | (74.00%) |  |  |  |  |  |  |  |  |  | (74.00%)
Nexium | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 145 |  |  |  |  |  |  |  |  |  | $ 756
Actual %, year-on-year | 9.00% |  |  |  |  |  |  |  |  |  | (15.00%)
CER %, year-on-year | 12.00% |  |  |  |  |  |  |  |  |  | (11.00%)
Losec/Prilosec |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 68 | 76 | 60 | 67 | 76 | 69 | 69 | 66 | 68 | 68 | $ 13
Actual %, year-on-year | (11.00%) |  |  |  |  |  |  |  |  |  | (24.00%)
CER %, year-on-year | (4.00%) |  |  |  |  |  |  |  |  |  | (24.00%)
Losec/Prilosec | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 45 |  |  |  |  |  |  |  |  |  | $ 96
Actual %, year-on-year | 7.00% |  |  |  |  |  |  |  |  |  | 9.00%
CER %, year-on-year | 17.00% |  |  |  |  |  |  |  |  |  | 17.00%
Losec/Prilosec | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 3 |  |  |  |  |  |  |  |  |  | $ 4
Losec/Prilosec | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 13 |  |  |  |  |  |  |  |  |  | $ 31
Actual %, year-on-year | (35.00%) |  |  |  |  |  |  |  |  |  | (14.00%)
CER %, year-on-year | (30.00%) |  |  |  |  |  |  |  |  |  | (8.00%)
Losec/Prilosec | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 7 |  |  |  |  |  |  |  |  |  | $ 144
Actual %, year-on-year | (36.00%) |  |  |  |  |  |  |  |  |  | (1.00%)
CER %, year-on-year | (36.00%) |  |  |  |  |  |  |  |  |  | 6.00%
Synagis |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 96 | 53 | 251 | 164 | 26 | 224 | 234 | 153 | 70 | 230 |
Synagis | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 10 |  |  |  |  |  |  |  |  |  | $ 35
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | (72.00%)
Synagis | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 86 |  |  |  |  |  |  |  |  |  | $ 114
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | (9.00%)
CER %, year-on-year |  |  |  |  |  |  |  |  |  |  | (9.00%)
Synagis | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales |  |  |  |  |  |  |  |  |  |  | $ 149
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | (40.00%)
CER %, year-on-year |  |  |  |  |  |  |  |  |  |  | (40.00%)
Seroquel XR/IR |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 32 | 37 | 56 | 77 | 131 | 97 | 156 | 113 | 135 | 104 | $ 11
Actual %, year-on-year | (76.00%) |  |  |  |  |  |  |  |  |  | (39.00%)
CER %, year-on-year | (74.00%) |  |  |  |  |  |  |  |  |  | (39.00%)
Seroquel XR/IR | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 10 |  |  |  |  |  |  |  |  |  | $ 24
Actual %, year-on-year | (81.00%) |  |  |  |  |  |  |  |  |  | (74.00%)
CER %, year-on-year | (81.00%) |  |  |  |  |  |  |  |  |  | (72.00%)
Seroquel XR/IR | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ (7) |  |  |  |  |  |  |  |  |  | $ (13)
Seroquel XR/IR | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 24 |  |  |  |  |  |  |  |  |  | $ 47
Actual %, year-on-year | (14.00%) |  |  |  |  |  |  |  |  |  | (16.00%)
CER %, year-on-year | (7.00%) |  |  |  |  |  |  |  |  |  | (13.00%)
Seroquel XR/IR | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 5 |  |  |  |  |  |  |  |  |  | $ 69
Actual %, year-on-year | (50.00%) |  |  |  |  |  |  |  |  |  | (70.00%)
CER %, year-on-year | (50.00%) |  |  |  |  |  |  |  |  |  | (68.00%)
Movantik/Moventig |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 22 | 25 | 25 | 32 | 24 | 28 | 30 | 30 | 32 | 30 |
Actual %, year-on-year | (8.00%) |  |  |  |  |  |  |  |  |  |
CER %, year-on-year | (8.00%) |  |  |  |  |  |  |  |  |  |
Movantik/Moventig | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 22 |  |  |  |  |  |  |  |  |  | $ 45
Actual %, year-on-year | (4.00%) |  |  |  |  |  |  |  |  |  | (12.00%)
Movantik/Moventig | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales |  |  |  |  |  |  |  |  |  |  | $ 2
Movantik/Moventig | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales |  |  |  |  |  |  |  |  |  |  | $ 47
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | (10.00%)
CER %, year-on-year |  |  |  |  |  |  |  |  |  |  | (10.00%)
FluMist/Fluenz |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales |  |  | 75 | 35 |  |  | 58 | 20 |  |  |
Other, Others |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 30 | $ 22 | $ 35 | $ 35 | $ 48 | $ 63 | $ 120 | $ 140 | $ 173 | $ 105 | $ 5
Actual %, year-on-year | (36.00%) |  |  |  |  |  |  |  |  |  | (86.00%)
CER %, year-on-year | (26.00%) |  |  |  |  |  |  |  |  |  | (69.00%)
Other, Others | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 16 |  |  |  |  |  |  |  |  |  | $ 10
Actual %, year-on-year | (53.00%) |  |  |  |  |  |  |  |  |  | (70.00%)
CER %, year-on-year | (47.00%) |  |  |  |  |  |  |  |  |  |
Other, Others | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 8 |  |  |  |  |  |  |  |  |  | $ 11
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | 57.00%
Other, Others | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 13 |  |  |  |  |  |  |  |  |  | $ 26
Actual %, year-on-year | 30.00% |  |  |  |  |  |  |  |  |  | (26.00%)
CER %, year-on-year | 60.00% |  |  |  |  |  |  |  |  |  | 14.00%
Other, Others | World |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ (7) |  |  |  |  |  |  |  |  |  | $ 52
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | (53.00%)
CER %, year-on-year |  |  |  |  |  |  |  |  |  |  | (49.00%)

X
- Definition Represents the increase (decrease) in revenue based on constant exchange rate, year-on-year, as a percent. + References No definition available. + Details
Name: | azn_IncreaseDecreaseInRevenueConstantExchangeRateYearOnYearAsPercentage
Namespace Prefix: | azn_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the actual increase (decrease) in revenue, year-on-year, as a percent. + References No definition available. + Details
Name: | azn_IncreaseDecreaseInRevenueYearOnYearPercentage
Namespace Prefix: | azn_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2018-01-01 -Paragraph 113 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=15&date=2018-03-01&anchor=para_113_a&doctype=Standard -URIDate 2018-03-16 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2018-01-01 -Paragraph 114 -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=15&date=2018-03-01&anchor=para_114&doctype=Standard -URIDate 2018-03-16 + Details
Name: | ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=azn_EmergingMarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=azn_IfrsCountryUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=azn_IfrsEuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=azn_WorldExcludingEmergingMarketsUnitedStatesAndEuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_OncologyProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_TagrissoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_ImfinziMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_LynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_IressaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_CalquenceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_FaslodexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_ZoladexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_ArimidexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_CasodexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_OtherOncologyProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_CardiovascularRenalAndMetabolismProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_FarxigaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_BrilintaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_OnglyzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_BydureonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_ByettaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_SymlinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_CrestorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_SelokenToprolXlMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_AtacandMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_OtherCardiovascularRenalAndMetabolismProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_RespiratoryProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_SymbicortMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_PulmicortMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_FasenraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_DalirespDaxasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_TudorzaEkliraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_DuaklirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_BevespiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_OtherRespiratoryProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_OtherProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_NexiumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_LosecPrilosecMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_SynagisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_SeroquelXrIrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_MovantikMoventigMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_FlumistFluenzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_OtherProductsOthersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |